Clinical Evaluation of FOXO1 as a Tumor Suppressor in Prostate Cancer

Table 1

Correlation between FOXO1 expression and clinicopathologic features in PCa patients.

Features	Number	FOXO1 expression		value
		Low	High
Age ()
<60	183	88	95	0.0362
>60	197
Pathological stage (pT) ()
pT2a-pT2c	157	72	85	0.2908
pT3a-pT4	221	118	103
Lymph node status ()
Positive	51	32	19	0.0032
Negative	261	121	140
Preoperation PSA level (ng/ml) (); Median (range)				0.0841
Gleason score ()
	243	100	123	0.0057
	137	70	47
Biochemical recurrence()
Yes	34	24	10	0.0016
No	281	131	150

, , .